Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
[Advanced]

The most recent version of this article was published on 1 May 2008

Thorax. Published Online First: 1 February 2008. doi:10.1136/thx.2007.086785
Copyright © 2008 BMJ Publishing Group Ltd & British Thoracic Society

This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
thx.2007.086785v1
63/5/447    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Menéndez, R.
Right arrow Articles by Torres, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Menéndez, R.
Right arrow Articles by Torres, A.
Topic Collections
Right arrowRelevant Article

Papers

Markers Of Treatment Failure In Hospitalized Community-Acquired Pneumonia

Rosario Menéndez 1*, Manuela Cavalcanti 2, Soledad Reyes 3, José Mensa 4, Raquel Martinez 3, María A Marcos 4, Xavier Filella 4, Michael Niederman 5 and Antoni Torres 6

1 Hospital Universitario La Fe, Spain
2 research fellow from Pavilhao Pereira Filho, PPG Pneumologia-UFRGS, Brazil
3 Hospital Universitario La Fe, Valencia, Spain
4 Hospital Clinic, Barcelona, Spain
5 Winthrop University Hospital, Mineola, New York, United States
6 Hospital Clinic, Spain

* To whom correspondence should be addressed. E-mail: rmenend{at}separ.es.

Accepted 12 December 2007


*   Abstract

Background: Lack of response to treatment in community-acquired pneumonia (CAP) worsens outcome. We evaluated the systemic cytokine profile -TNF{alpha}, IL1, IL6, IL8 and IL10- C-reactive protein (CRP) and procalcitonin (PCT) in patients with CAP who had treatment failure.

Methods: A prospective study was performed in hospitalized patients with CAP. Cytokines, PCT and CRP measurements were obtained on day 1 and after 72 hours of treatment. Treatment failure was the endpoint evaluated, with separation of those with early (≤72hours) or late failure.

Results: 453 patients were included: 84 (18 %) had treatment failure, of which 38(8 %) were early failure. The median levels of IL-6, PCT and CRP on days 1 and 3 and the median level of IL-8 on day 1 were significantly higher in patients with any treatment failure. Logistic regression analysis demonstrated that values above the following cut-off points for IL-6 (≥169 pg/ml), IL-8 (≥14)and CRP (≥21.9 mg/dl), on day 1 had independent predictive value for any treatment failure after adjustment for initial severity; relative risks (OR) found were 1.9, 2.2 and 2.6 respectively. Increased levels for CRP and PCT at day 1 were also independent predictors for early failure. Increased levels for IL-6 and CRP were the best predictors of late failure.

Conclusions: Serum levels of CRP, IL-6 and PCT on days 1 and 3 are independently associated with a higher risk of any treatment failure. Low levels of PCT and CRP on day one have a high negative predictive value for early failure


Keywords: c reactive protein, cytokine, failure, pneumonia, procalcitonin


Relevant Article

Airwaves
Wisia Wedzicha
Thorax 2008 63: 387. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
Eur Respir JHome page
A. H. W. Bruns, J. J. Oosterheert, E. Hak, and A. I. M. Hoepelman
Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia
Eur. Respir. J., September 1, 2008; 32(3): 726 - 732.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 BMJ Publishing Group Ltd & British Thoracic Society